Clinical Trial Update: Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5 [Phase 2]

View source ↗

Summary

A phase 2 trial will add naxitamab and GM-CSF to the standard COG-type induction therapy for newly diagnosed high-risk neuroblastoma in patients aged 12 months …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• DANYELZA (NAXITAMAB)
• Leukine (sargramostim)

Snippet

Sponsor: Shaare Zedek Medical Center | Conditions: High-Risk Neuroblastoma | Phase 2 | Status: NOT_YET_RECRUITING